Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Phathom Pharmaceuticals' Amortization of Deferred Charges rose 1592.92% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 2503.45%. This contributed to the annual value of $3.8 million for FY2024, which is 535.86% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $1.2 million for Q3 2025, which was up 1592.92% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $1.2 million in Q3 2025 and a low of $806000.0 during Q1 2024
  • Over the past 4 years, Phathom Pharmaceuticals' median Amortization of Deferred Charges value was $899000.0 (recorded in 2023), while the average stood at $954733.3.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first crashed by 809.58% in 2024, then surged by 4156.33% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' Amortization of Deferred Charges stood at $890000.0 in 2022, then rose by 1.01% to $899000.0 in 2023, then grew by 16.91% to $1.1 million in 2024, then increased by 12.18% to $1.2 million in 2025.
  • Its Amortization of Deferred Charges stands at $1.2 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.1 million for Q1 2025.